^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CEP-37440

    i
    Associations
    News

    Trials

    Company:
    Teva
    Drug class:
    ALK inhibitor, FAK inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors (NCT01922752)
    Phase 1
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    11/12/2021
    Initiation :
    07/01/2013
    Primary completion :
    09/01/2015
    Completion :
    12/01/2015
    ALK
    |
    ALK positive
    |
    CEP-37440